Cart 0
Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders
Click to zoom

Share this book

Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders

Softcover reprint of the original 1st ed. 2017

Book Details

Format Paperback / Softback
ISBN-10 3319851586
ISBN-13 9783319851587
Edition Softcover reprint of the original 1st ed. 2017
Publisher Springer International Publishing AG
Imprint Springer International Publishing AG
Country of Manufacture CH
Country of Publication GB
Publication Date May 8th, 2018
Print length 220 Pages
Ksh 23,400.00
Werezi Extended Catalogue 0 in stock

Delivery Location

Delivery fee: Select location

Secure
Quality
Fast
In this book, leading international experts analyze state-of-the-art advances in gene transfer vectors for applications in inherited disorders and also examine the toxicity profiles of these methods.
In this book, leading international experts analyze state-of-the-art advances in gene transfer vectors for applications in inherited disorders and also examine the toxicity profiles of these methods. The authors discuss the strengths and weaknesses of available vectors in the clinical setting, and specifically focus on the challenges and possible solutions that researchers are testing in order to improve the safety of gene therapy for genetic diseases. This comprehensive and authoritative overview of vector development is a necessary text for researchers, toxicologists, pharmacologists, molecular biologists, physicians, and students in these fields.

Get Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Springer International Publishing AG and it has pages.

Mind, Body, & Spirit

Shopping Cart

Africa largest book store

Sub Total:
Ebooks

Digital Library
Coming Soon

Our digital collection is currently being curated to ensure the best possible reading experience on Werezi. We'll be launching our Ebooks platform shortly.